Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hepatology
Volume 2013, Article ID 964828, 3 pages
http://dx.doi.org/10.1155/2013/964828
Case Report

Tocilizumab-Induced Acute Liver Injury in Adult Onset Still’s Disease

1Division of Gastroenterology and Hepatology, Department of Internal Medecine Specialties, Geneva University Hospital, Rue Gabrielle Perret Gentil 4, 1211 Geneva 14, Switzerland
2Division of Clinical Pathology, Geneva University Hospital and Geneva Faculty of Medicine, Rue Gabrielle Perret Gentil 4, 1211 Geneva 14, Switzerland

Received 30 April 2013; Accepted 6 June 2013

Academic Editors: F. Imazeki, J. Kaneko, G. H. Koek, F. Pérez Roldán, Y. Sugawara, and M. Vigano

Copyright © 2013 Michael Drepper et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Sakai, H. Nagasawa, E. Nishi et al., “Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review,” Clinical Rheumatology, vol. 31, no. 3, pp. 569–574, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Suematsu, A. Ohta, E. Matsuura et al., “Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan,” Modern Rheumatology, vol. 22, pp. 712–719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D.-Y. Chen, J.-L. Lan, F.-J. Lin, and T.-Y. Hsieh, “Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still's disease,” Journal of Rheumatology, vol. 31, no. 11, pp. 2189–2198, 2004. View at Google Scholar · View at Scopus
  4. C. Drucker, J. Gewiese, S. Malchow, J. Scheller, and S. Rose-John, “Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration,” Journal of Autoimmunity, vol. 34, no. 1, pp. 29–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Smolen, M. M. Schoels, N. Nishimoto et al., “Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions,” Annals of the Rheumatic Diseases, vol. 72, pp. 482–492, 2013. View at Google Scholar
  6. F. de Benedetti, H. I. Brunner, N. Ruperto et al., “Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis,” The New England Journal of Medicine, vol. 367, pp. 2385–2395, 2012. View at Google Scholar
  7. H. de Boysson, J. Fevrier, A. Nicolle, C. Auzary, and L. Geffray, “Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence,” Clinical Rheumatology, vol. 32, pp. 141–147, 2013. View at Google Scholar
  8. W. M. Lee, L. S. Hynan, L. Rossaro et al., “Intravenous N-acetylcysteine improves transplant-free survival in early stage non acetaminophen acute liver failure,” Gastroenterology, vol. 137, no. 3, pp. 856.e1–864.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Singh, L. S. Hynan, and W. M. Lee, “Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non- acetaminophen acute liver failure,” Digestive Diseases and Sciences, vol. 58, pp. 1397–1402, 2013. View at Google Scholar
  10. R. M. Gallagher, J. J. Kirkham, J. R. Mason et al., “Development and inter-rater reliability of the liverpool adverse drug reaction causality assessment tool,” PLoS ONE, vol. 6, no. 12, Article ID e28096, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kovalovich, R. A. Deangelis, W. Li, E. E. Furth, G. Ciliberto, and R. Taub, “Increased toxin-induced liver injury and fibrosis in interleukin-6- deficient mice,” Hepatology, vol. 31, no. 1, pp. 149–159, 2000. View at Google Scholar · View at Scopus
  12. N. Nishimoto, K. Ito, and N. Takagi, “Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions,” Modern Rheumatology, vol. 20, no. 3, pp. 222–232, 2010. View at Google Scholar · View at Scopus
  13. G. Jones and C. Ding, “Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis,” Clinical Medicine Insights, vol. 3, pp. 81–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Mahamid, K. Paz, M. Reuven, and R. Safadi, “Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports,” International Journal of General Medicine, vol. 4, pp. 657–660, 2011. View at Google Scholar
  15. M. Hiura, S. Abe, A. Tabaru et al., “Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis,” Hepatology Research, vol. 41, no. 5, pp. 492–496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Alfreijat, M. Habibi, P. Bhatia, and A. Bhatia, “Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis,” Rheumatology, vol. 52, pp. 1340–1341, 2013. View at Google Scholar
  17. M. García-Cortés, C. Stephens, M. I. Lucena, A. Fernández-Castañer, and R. J. Andrade, “Causality assessment methods in drug induced liver injury: strengths and weaknesses,” Journal of Hepatology, vol. 55, no. 3, pp. 683–691, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. T. Suk, D. J. Kim, C. H. Kim et al., “A prospective nationwide study of drug-induced liver injury in Korea,” The American Journal of Gastroenterology, vol. 107, pp. 1380–1387, 2012. View at Google Scholar
  19. X.-D. Kong, D. Xu, W. Zhang, Y. Zhao, X. Zeng, and F. Zhang, “Clinical features and prognosis in adult-onset still's disease: a study of 104 cases,” Clinical Rheumatology, vol. 29, no. 9, pp. 1015–1019, 2010. View at Publisher · View at Google Scholar · View at Scopus